Ahuvit is an Associate at aMoon Edge, where she brings a deep understanding of public therapeutics companies spanning the spectrum of early-to-late-clinical stages.
Before joining aMoon, Ahuvit served as an analyst at Medison Pharma's strategic investments arm as well as their healthcare-focused hedge fund. Through her investment activities, she established wide medical and scientific knowledge regarding multiple therapeutic areas and supported the decision making of the corporate development and market research teams.
Ahuvit has several years of experience as a scientist working in academic centers and at a biotech startup where she has gained interdisciplinary expertise in various research fields and techniques. Her research has been included in 14 research papers and has been recognized with numerous excellence and fellowship awards.
During her PhD work at Sheba Medical Center, in collaboration with the German Cancer Research Center (DKFZ), Ahuvit helped define mutant mouse embryos devoid of centrosomes, a cellular structure essential for cell division. This research was the first of its kind and advanced basic concepts in cell and developmental biology related to centrosome formation and functions during mammalian embryogenesis. Additionally, this model was utilized to characterize mutations in centrosome genes causing primary microcephaly, a severe congenital disorder characterized by small brain size.
Ahuvit completed her postdoctoral studies at Tel-Aviv University, and The Netherlands Cancer Institute, NKI, where she uncovered a new genetic risk factor of adult-onset macular degeneration (AMD) by combining a map of gene regulatory sites with disease-associated loci.
Ahuvit holds a BSc (With Excellence) and MSc (Summa Cum Laude) in Biotechnology from Bar-Ilan University.